AtTEnd - Atezolizumab in Endometrial cancer
Research type
Research Study
Full title
Phase III Double-blind, randomised, placebo controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/ recurrent endometrial cancer
IRAS ID
251207
Contact name
Emma Hudson
Contact email
Sponsor organisation
Mario Negri Gynecology Oncology Group (MaNGO)
Eudract number
2018-001072-37
Clinicaltrials.gov Identifier
Duration of Study in the UK
4 years, 0 months, 0 days
Research summary
The study will assess the efficacy of atezolizumab compared to placebo, against a background of a standard chemotherapy regime (carboplatin and paclitaxel) in women with advanced or recurrent endometrial cancer.\nAtezolizumab has been recently licenced for urothelial cancer and an earlier small pilot study showed an Overall Response Rate in 15% of the patients.\nAtezolizumab is an immunotherapy which is targeted against the PD-L1 (a lymphocyte protein involved in stopping programmed cell death). This target has been identified as being important in tumours with a highly mutated cancers, such as endometrial cancer.\nAdvanced or recurrent endometrial cancer patients are associated with a very poor prognosis.
REC name
Wales REC 3
REC reference
18/WA/0417
Date of REC Opinion
29 Jan 2019
REC opinion
Further Information Favourable Opinion